Ames negative; chromosomal aberrations in vitro; negative in vivo rat micronucleus and liver comet assays
“non-mutagenic in Ames test, increased chromosomal aberrations in vitro but not considered clastogenic in the in vivo rat micronucleus assay and did not induce DNA damage in the Comet assay in rat hepatocytes”
Not conducted (short treatment duration, generally 14 days or less)
“Carcinogenicity studies were not conducted. CHMP agreed that carcinogenicity studies were not needed as the SmPC states that the duration of dosing will be generally 14 days or less (not exceeding 21 days).”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Mouse and rat EFD: no developmental toxicity up to 2000 (mouse, SC) and 1000 (rat, IV) mg/kg/day
“Cefiderocol did not cause developmental toxicity in mice when administered to dams at daily subcutaneous doses up to 2000 mg/kg/day (twice daily 1000 mg/kg doses) from GD 6-15. It did not cause developmental toxicity in rats when administered intravenously to dams at doses up to 1000 mg/kg/day from GD 6-17.”
✓ VerifiedFDA multi-discipline review, p. 47Source ↗
Safety pharmacology
QTc prolongation in cynomolgus monkeys at 1000 mg/kg IV, in safety pharmacology and repeat-dose studies
“Prolongation of the QTc (Bazett) was observed in cynomolgus monkeys following a 1000 mg/kg dose given intravenously over 1 hour (observed in both a single dose safety pharmacology study and in repeat dose toxicology studies).”
✓ VerifiedFDA multi-discipline review, p. 47Source ↗
Genotox: Ames
Negative (S. typhimurium and E. coli reverse mutation)
“Cefiderocol was negative for genotoxicity in a reverse mutation test with S. typhimurium and E. coli and did not induce mutations in V79 Chinese hamster lung cells.”
Positive: chromosomal aberration in TK6 human lymphoblasts and mouse lymphoma L5178Y assay
“Cefiderocol was positive in a chromosomal aberration test in cultured TK6 human lymphoblasts and increased mutation frequency in L5178Y mouse lymphoma cells.”
Not conducted (dosing generally 14 days or less, not exceeding 21 days)
“Carcinogenicity studies were not conducted. CHMP agreed that carcinogenicity studies were not needed as the SmPC states that the duration of dosing will be generally 14 days or less (not exceeding 21 days).”
Not needed: dosing generally 14 days or less (not exceeding 21 days)
“Carcinogenicity studies were not conducted. CHMP agreed that carcinogenicity studies were not needed as the SmPC states that the duration of dosing will be generally 14 days or less (not exceeding 21 days).”
Minor hERG inhibition: 12% at 1.5 mg/mL, IC50 > 1.5 mg/mL
“The study conducted in HEK293 cells stably expressing hERG channels, indicate a dose related suppression of hERG, being 12 % at the highest dose (1.5 mg/mL) and hence an IC50 > 1.5 mg/mL.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative